Exelixis Inc (NASDAQ: EXEL) kicked off on Monday, down -4.94% from the previous trading day, before settling in for the closing price of $44.36. Over the past 52 weeks, EXEL has traded in a range of $31.90-$49.62.
A company in the Healthcare sector has jumped its sales by 11.55% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 64.54%. With a float of $259.68 million, this company’s outstanding shares have now reached $268.10 million.
Exelixis Inc (EXEL) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Exelixis Inc is 3.15%, while institutional ownership is 95.93%. The most recent insider transaction that took place on Nov 25 ’25, was worth 1,187,235. In this transaction Director of this company bought 27,532 shares at a rate of $43.12, taking the stock ownership to the 1,553,262 shares. Before that another transaction happened on Nov 20 ’25, when Company’s EVP, Commercial sold 34,187 for $41.88, making the entire transaction worth $1,431,757. This insider now owns 0 shares in total.
Exelixis Inc (EXEL) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.55 earnings per share (EPS), higher than consensus estimate (set at 0.49) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 64.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.57% during the next five years compared to 11.55% growth over the previous five years of trading.
Exelixis Inc (NASDAQ: EXEL) Trading Performance Indicators
Take a look at Exelixis Inc’s (EXEL) current performance indicators. Last quarter, stock had a quick ratio of 3.68. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.94. Likewise, its price to free cash flow for the trailing twelve months is 14.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.38, a number that is poised to hit 0.76 in the next quarter and is forecasted to reach 3.23 in one year’s time.
Technical Analysis of Exelixis Inc (EXEL)
Let’s dig in a bit further. During the last 5-days, its volume was 2.58 million. That was inferior than the volume of 2.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 57.39%.
During the past 100 days, Exelixis Inc’s (EXEL) raw stochastic average was set at 66.39%, which indicates a significant increase from 15.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.12 in the past 14 days, which was lower than the 1.14 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $40.67, while its 200-day Moving Average is $39.88. However, in the short run, Exelixis Inc’s stock first resistance to watch stands at $43.88. Second resistance stands at $45.59. The third major resistance level sits at $46.59. If the price goes on to break the first support level at $41.17, it is likely to go to the next support level at $40.17. The third support level lies at $38.46 if the price breaches the second support level.
Exelixis Inc (NASDAQ: EXEL) Key Stats
The company with the Market Capitalisation of 11.31 billion has total of 268,112K Shares Outstanding. Its annual sales at the moment are 2,169 M in contrast with the sum of 521,270 K annual income. Company’s last quarter sales were recorded 597,760 K and last quarter income was 193,580 K.
